CN1262272C - 用于预防或治疗运动障碍的氨基甲酸酯化合物 - Google Patents

用于预防或治疗运动障碍的氨基甲酸酯化合物 Download PDF

Info

Publication number
CN1262272C
CN1262272C CNB028089243A CN02808924A CN1262272C CN 1262272 C CN1262272 C CN 1262272C CN B028089243 A CNB028089243 A CN B028089243A CN 02808924 A CN02808924 A CN 02808924A CN 1262272 C CN1262272 C CN 1262272C
Authority
CN
China
Prior art keywords
formula
purposes
enantiomer
tremor
dyskinesia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028089243A
Other languages
English (en)
Chinese (zh)
Other versions
CN1505508A (zh
Inventor
C·R·普拉塔-萨拉曼
赵柏羽
R·E·特伊曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1505508A publication Critical patent/CN1505508A/zh
Application granted granted Critical
Publication of CN1262272C publication Critical patent/CN1262272C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028089243A 2001-02-27 2002-02-21 用于预防或治疗运动障碍的氨基甲酸酯化合物 Expired - Fee Related CN1262272C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US60/271,683 2001-02-27
US10/081,501 2002-02-21
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (2)

Publication Number Publication Date
CN1505508A CN1505508A (zh) 2004-06-16
CN1262272C true CN1262272C (zh) 2006-07-05

Family

ID=26765643

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028089243A Expired - Fee Related CN1262272C (zh) 2001-02-27 2002-02-21 用于预防或治疗运动障碍的氨基甲酸酯化合物

Country Status (27)

Country Link
US (1) US6589985B2 (https=)
EP (1) EP1411917B1 (https=)
JP (1) JP2004527492A (https=)
KR (1) KR100858232B1 (https=)
CN (1) CN1262272C (https=)
AR (1) AR033426A1 (https=)
AT (1) ATE369130T1 (https=)
AU (1) AU2002247204B2 (https=)
BR (1) BR0207831A (https=)
CA (1) CA2439478C (https=)
CY (1) CY1106924T1 (https=)
CZ (1) CZ20032299A3 (https=)
DE (1) DE60221670T2 (https=)
DK (1) DK1411917T3 (https=)
ES (1) ES2291454T3 (https=)
HU (1) HUP0303344A3 (https=)
IL (2) IL157592A0 (https=)
MX (1) MXPA03007719A (https=)
MY (1) MY157373A (https=)
NO (1) NO20033803L (https=)
NZ (1) NZ551954A (https=)
PL (1) PL364679A1 (https=)
PT (1) PT1411917E (https=)
RS (1) RS50676B (https=)
RU (1) RU2294739C2 (https=)
TW (1) TWI331524B (https=)
WO (1) WO2002067926A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267629T1 (de) * 2000-07-21 2004-06-15 Ortho Mcneil Pharm Inc Verwendung von carbamat verbindungen zur vorbeugung oder behandlung von neuropathischen- , cluster- und migräneartigen kopfschmerzen
EP1383489B1 (en) * 2001-02-27 2007-05-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
ATE435014T1 (de) 2001-07-16 2009-07-15 Ortho Mcneil Pharm Inc Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen
EP1890684B1 (en) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
ES2385087T3 (es) * 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN105189451A (zh) 2013-03-12 2015-12-23 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
US11033531B2 (en) * 2016-12-14 2021-06-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR20230044274A (ko) * 2020-08-31 2023-04-03 (주)바이오팜솔루션즈 신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
ATE369130T1 (de) 2007-08-15
CZ20032299A3 (cs) 2004-08-18
TWI331524B (en) 2010-10-11
EP1411917A1 (en) 2004-04-28
DE60221670D1 (de) 2007-09-20
AU2002247204B2 (en) 2006-08-24
CN1505508A (zh) 2004-06-16
US6589985B2 (en) 2003-07-08
DK1411917T3 (da) 2007-09-24
YU67703A (sh) 2006-08-17
MXPA03007719A (es) 2004-11-12
KR100858232B1 (ko) 2008-09-12
HK1067305A1 (en) 2005-04-08
BR0207831A (pt) 2004-06-22
AR033426A1 (es) 2003-12-17
CY1106924T1 (el) 2012-09-26
NO20033803D0 (no) 2003-08-26
HUP0303344A2 (hu) 2004-01-28
CA2439478A1 (en) 2002-09-06
PT1411917E (pt) 2007-09-17
HUP0303344A3 (en) 2012-07-30
ES2291454T3 (es) 2008-03-01
DE60221670T2 (de) 2008-04-30
RS50676B (sr) 2010-06-30
NO20033803L (no) 2003-10-10
JP2004527492A (ja) 2004-09-09
NZ551954A (en) 2008-07-31
MY157373A (en) 2016-06-15
US20020151585A1 (en) 2002-10-17
PL364679A1 (en) 2004-12-13
IL157592A0 (en) 2004-03-28
WO2002067926A1 (en) 2002-09-06
IL157592A (en) 2009-12-24
KR20030074847A (ko) 2003-09-19
CA2439478C (en) 2010-05-18
RU2294739C2 (ru) 2007-03-10
EP1411917B1 (en) 2007-08-08
RU2003128985A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
CN1262272C (zh) 用于预防或治疗运动障碍的氨基甲酸酯化合物
JP5901528B2 (ja) 線維筋痛症候群の治療方法
AU2005302589B2 (en) Adjunctive therapy for depression
AU2002247204A1 (en) Carbamate compounds for use in preventing or treating movement disorders
CN1235579C (zh) 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
CN1250214C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN1250215C (zh) 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
WO2008055022A2 (en) Carbamate compounds for use in treating depression
CN1250213C (zh) 用于预防或治疗神经性疼痛和丛集性头痛及有或没有先兆的偏头痛的氨基甲酸酯化合物
CA2454047C (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
HK1067305B (en) Carbamate compounds for use in preventing or treating movement disorders
AU2002354909A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
ZA200401155B (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060705

Termination date: 20120221